MedTrace Logo

Effect of Metformin Therapy on Serum Under-carboxylated Osteocalcin Levels in Hyperandrogenic Lean Polycystic Ovarian Syndrome Women

NCT02244567 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-02-02

No results posted yet for this study

Summary

High ucOC may favor insulin release in lean hyperandrogenic women to compensate for impaired insulin sensitivity. Meformin is an insulin sensitizing agent will be given for these women trying to interfere with the pathophysiology of PCOS in these women as followed up by serum UC-OC levels.

Conditions

  • Polycystic Ovarian Syndrome

Interventions

DRUG

Metformin 850 mg twice daily for 3 months

This drug is insulin sensitizing agent which will be given twice daily orally for 3 months for PCOS patients.

PROCEDURE

Serum uc-oc

Serum uc-oc is a bone biomarker involved in incraesing insulin in pathophysiology of PCOS. It will be measured in serum of pcos patients before and after treatment with metformin for 3 months.

OTHER

drug

This group of patients will receive any type of vitamin as a placebo to compare with effect of Metformin on serum UC-OC.

Sponsors & Collaborators

  • Cairo University

    collaborator OTHER

  • Beni-Suef University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
30 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02244567 on ClinicalTrials.gov